Tianjin Lisheng Pharmaceutical Co.,Ltd.

SZSE:002393 Stok Raporu

Piyasa değeri: CN¥4.3b

Tianjin Lisheng PharmaceuticalLtd Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 2/6

Tianjin Lisheng PharmaceuticalLtd has been growing earnings at an average annual rate of 22.3%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been declining at an average rate of 4.8% per year. Tianjin Lisheng PharmaceuticalLtd's return on equity is 3.7%, and it has net margins of 14.9%.

Anahtar bilgiler

22.3%

Kazanç büyüme oranı

22.2%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi10.9%
Gelir büyüme oranı-4.8%
Özkaynak getirisi3.7%
Net Marj14.9%
Son Kazanç Güncellemesi30 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

These 4 Measures Indicate That Tianjin Lisheng PharmaceuticalLtd (SZSE:002393) Is Using Debt Safely

Sep 28
These 4 Measures Indicate That Tianjin Lisheng PharmaceuticalLtd (SZSE:002393) Is Using Debt Safely

Tianjin Lisheng PharmaceuticalLtd (SZSE:002393) Strong Profits May Be Masking Some Underlying Issues

Mar 28
Tianjin Lisheng PharmaceuticalLtd (SZSE:002393) Strong Profits May Be Masking Some Underlying Issues

Gelir ve Gider Dağılımı

Tianjin Lisheng PharmaceuticalLtd nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

SZSE:002393 Gelir, gider ve kazançlar (CNY Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Sep 241,265188453119
30 Jun 241,24037444891
31 Mar 241,182374425103
31 Dec 231,153362429102
30 Sep 231,15632444191
30 Jun 231,189112466103
31 Mar 231,17698467100
01 Jan 231,14794449102
30 Sep 221,158137481111
30 Jun 221,119133469107
31 Mar 221,071128450101
01 Jan 221,092122466101
30 Sep 211,0612744894
30 Jun 211,1141348293
31 Mar 211,1361051078
31 Dec 201,141954773
30 Sep 201,32113364382
30 Jun 201,37415668690
31 Mar 201,513178773102
31 Dec 191,615188813120
30 Sep 191,61321583975
30 Jun 191,58920583874
31 Mar 191,54418879887
31 Dec 181,50418576992
30 Sep 181,366122707129
30 Jun 181,273107564188
31 Mar 181,138117479144
01 Jan 181,029117420101
30 Sep 1797513734885
30 Jun 179151253940
31 Mar 178961143860
31 Dec 168471163500
30 Sep 16792743270
30 Jun 16769773040
31 Mar 167791102950
31 Dec 157751142910
30 Sep 157621043010
30 Jun 157591043070
31 Mar 15725753010
31 Dec 14774933230
30 Sep 148511293370
30 Jun 149251783450
31 Mar 141,0162523650
31 Dec 131,0442933510

Kaliteli Kazançlar: 002393 has high quality earnings.

Büyüyen Kar Marjı: 002393's current net profit margins (14.9%) are lower than last year (28%).

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 002393's earnings have grown significantly by 22.3% per year over the past 5 years.

Büyüme Hızlandırma: 002393's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Kazançlar vs. Sektör: 002393 had negative earnings growth (-41.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.2%).

Özkaynak Getirisi

Yüksek ROE: 002393's Return on Equity (3.7%) is considered low.

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y